Multimodal Treatment Strategy for Clinical T3 Thoracic Esophageal Cancer

Purpose Our goal was to create a multimodal treatment strategy for patients with locally advanced esophageal cancer (EC). Methods A retrospective review identified a total of 193 patients with clinical T3 thoracic EC were categorized into 3 groups: 81 who had surgery only (group I); 102 who had plan...

Full description

Saved in:
Bibliographic Details
Published in:Annals of surgical oncology 2013-12, Vol.20 (13), p.4267-4273
Main Authors: Saeki, Hiroshi, Morita, Masaru, Tsuda, Yasuo, Hidaka, Gen, Kasagi, Yuta, Kawano, Hiroyuki, Otsu, Hajime, Ando, Koji, Kimura, Yasue, Oki, Eiji, Kusumoto, Tetsuya, Maehara, Yoshihiko
Format: Article
Language:English
Subjects:
Adenocarcinoma - mortality
Adenocarcinoma - pathology
Adenocarcinoma - therapy
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carcinoma, Squamous Cell - mortality
Carcinoma, Squamous Cell - pathology
Carcinoma, Squamous Cell - therapy
Case-Control Studies
Cisplatin - administration & dosage
Combined Modality Therapy
Esophageal Neoplasms - mortality
Esophageal Neoplasms - pathology
Esophageal Neoplasms - therapy
Esophagectomy
Female
Fluorouracil - administration & dosage
Follow-Up Studies
Humans
Male
Medicine
Medicine & Public Health
Middle Aged
Neoplasm Staging
Oncology
Prognosis
Radiotherapy Dosage
Retrospective Studies
Surgery
Surgical Oncology
Survival Rate
Thoracic Neoplasms - mortality
Thoracic Neoplasms - pathology
Thoracic Neoplasms - therapy
Thoracic Oncology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Our goal was to create a multimodal treatment strategy for patients with locally advanced esophageal cancer (EC). Methods A retrospective review identified a total of 193 patients with clinical T3 thoracic EC were categorized into 3 groups: 81 who had surgery only (group I); 102 who had planned neoadjuvant chemoradiotherapy (NACRT; group II); and 10 who had salvage esophagectomy after definitive chemoradiotherapy (dCRT; group III). Results Postoperative complications developed in 27, 45, and 80 % of patients in group I, group II, and group III, respectively. NACRT and dCRT were independent risk factors associated with postoperative complications; the odds ratios for group II and group III, compared with group I, were 2.1 and 8.8, respectively. The respective mortality rates were 4, 2, and 20 % (group I vs. group III, p  
ISSN:1068-9265
1534-4681
DOI:10.1245/s10434-013-3192-2